Literature DB >> 8053957

The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus.

G D Middleton1, J E McFarlin, P E Lipsky.   

Abstract

OBJECTIVE: To ascertain the prevalence of fibromyalgia syndrome (FMS) in systemic lupus erythematosus (SLE) and to evaluate its clinical impact and relationship to SLE disease activity.
METHODS: A cross-sectional analysis of 102 patients from a public hospital SLE clinic. Information was obtained on symptoms of FMS, disability, tender points, pain thresholds, and SLE disease activity.
RESULTS: Twenty-two SLE patients (22%) met the American College of Rheumatology criteria for FMS, and another 24 (23%) had clinical FMS but did not meet the classification criteria. The patients who met the criteria for FMS had a significantly increased frequency and severity of symptoms commonly associated with FMS, and were much more likely to be unable to perform daily activities. The FMS patients also were less likely to be employed, and more likely to be divorced and to be receiving welfare or medical disability benefits. However, patients with and those without FMS did not differ in measures of SLE activity.
CONCLUSION: FMS is very common in SLE patients, and accounts for many of the symptoms and much of the disability in these patients.

Entities:  

Mesh:

Year:  1994        PMID: 8053957     DOI: 10.1002/art.1780370812

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  28 in total

Review 1.  Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria.

Authors:  John McBeth; Matthew R Mulvey
Journal:  Nat Rev Rheumatol       Date:  2012-01-24       Impact factor: 20.543

Review 2.  Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis.

Authors:  Fatemeh Heidari; Mahdi Afshari; Mahmood Moosazadeh
Journal:  Rheumatol Int       Date:  2017-04-26       Impact factor: 2.631

3.  Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases.

Authors:  Roland Staud
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

4.  The prevalence of fibromyalgia in patients with Behçet's disease and its relation with disease activity.

Authors:  Mehmet Melikoglu; Meltem Alkan Melikoglu
Journal:  Rheumatol Int       Date:  2012-09-28       Impact factor: 2.631

5.  [Lupus in Germany: analysis within the German lupus self-help organization (LULA)].

Authors:  R Fischer-Betz; E Wessel; J Richter; B Winkler-Rohlfing; R Willers; M Schneider
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 6.  Quality-of-life measurements versus disease activity in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

7.  The FIBRO System: A Rapid Strategy for Assessment and Management of Fibromyalgia Syndrome.

Authors:  Chad S Boomershine
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

8.  Frequency of rheumatic diseases in patients with autoimmune thyroid disease.

Authors:  Mehmet Soy; Sibel Guldiken; Ender Arikan; Betul Ugur Altun; Armagan Tugrul
Journal:  Rheumatol Int       Date:  2006-11-11       Impact factor: 2.631

Review 9.  Central pain mechanisms in the rheumatic diseases: future directions.

Authors:  Kristine Phillips; Daniel J Clauw
Journal:  Arthritis Rheum       Date:  2013-02

10.  Predictors of self-reported health-related quality of life in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Vibeke Strand; Hong Fang; Jawali Jaranilla; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2013-05-16       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.